A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a technology-based company with a well-established laboratory services business and a therapeutic development business. Our laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Our therapeutic development business is focused on developing product candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs. Mission and Vision Founded in 2011, Fulgent began with two simple ideas: flexibility and affordability. We offer and develop flexible and affordable diagnostic and genetic tests and laboratory services designed to improve patient care and quality of life. We strive to provide the most effective and wide-ranging genetic and diagnostic testing menu on the market.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 323M | 323M | 283M | 289M | 619M | 993M |
| Net Income | -61M | -61M | -43M | -168M | 143M | 507M |
| EPS | $-1.97 | $-1.97 | $-1.41 | $-5.63 | $4.63 | $16.38 |
| Free Cash Flow | -124M | -124M | -19M | 4.8M | 235M | 515M |
| ROIC | -6.8% | -5.4% | -3.8% | -14.8% | 18.3% | 69.5% |
| Gross Margin | 40.6% | 40.6% | 37.8% | 36.1% | 59.3% | 78.3% |
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -91M | -91M | -74M | -196M | 179M | 676M |
| Operating Margin | -28.2% | -28.2% | -26.1% | -67.6% | 28.8% | 68.1% |
| ROE | -5.4% | -5.4% | -3.8% | -14.8% | 11.3% | 43.8% |
| Shares Outstanding | 31M | 31M | 30M | 30M | 31M | 31M |
Fulgent Genetics, Inc. passes 5 of 9 quality checks, suggesting mixed fundamentals.
The company's 5-year average ROIC is 12.8% with a gross margin of 50.4%. Total shareholder yield (buybacks) is 2.3%. At current prices, the estimated annualized return to fair value is -7.4%.
Fulgent Genetics, Inc. (FLGT) has a 5-year average return on invested capital (ROIC) of 12.8%. This indicates solid capital allocation.
Fulgent Genetics, Inc. (FLGT) has a market capitalization of $470M. It is classified as a small-cap stock.
Fulgent Genetics, Inc. (FLGT) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 2.32%.
Fulgent Genetics, Inc. (FLGT) operates in the Services-Medical Laboratories industry, within the Healthcare sector.
Fulgent Genetics, Inc. (FLGT) reported annual revenue of $323 million in its most recent fiscal year, based on SEC EDGAR filings.
Fulgent Genetics, Inc. (FLGT) has a net profit margin of -18.8%. The company is currently unprofitable.
Fulgent Genetics, Inc. (FLGT) generated $-124 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Fulgent Genetics, Inc. (FLGT) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
Fulgent Genetics, Inc. (FLGT) reported earnings per share (EPS) of $-1.97 in its most recent fiscal year.
Fulgent Genetics, Inc. (FLGT) has a return on equity (ROE) of -5.4%. A negative ROE may indicate losses or negative equity.
Fulgent Genetics, Inc. (FLGT) has a 5-year average gross margin of 50.4%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 11 years of financial data for Fulgent Genetics, Inc. (FLGT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Fulgent Genetics, Inc. (FLGT) has a book value per share of $36.20, based on its most recent annual SEC filing.